番茄社区app

Trial tested BI 690517 with and without empagliflozin

Multi-pronged approach to boost living and deceased donor transplant fails in randomized trial

Proteinuria reduction and slower eGFR decline in 2-year PROTECT trial

But ZENITH-CKD trial had to pivot to only using low-dose zibotentan due to fluid retention

However, more patients on the drug achieved partial remission of proteinuria vs irbesartan

APRIL-neutralizing antibody sibeprenlimab reduced proteinuria and stabilized eGFR

Researcher argued saline should be reconsidered as the standard IV fluid used

EHR pings improved outcomes in those on PPIs, but lacked general clinical impact

Some patients in MyTEMP trial even complained cooler dialysate was "worst possible feeling"

Also cut risk for cardiovascular-related death and worsening kidney function

Findings do not support discontinuation to improve kidney function, researchers say

Patients saw better eGFR recovery compared with prednisone

Study compared 6-month course to standard 3-month therapy

Researcher says TESTING study findings support new KDIGO guidelines